page hit counter Hympavzi Recommended for Approval in Europe for Severe Hemophilia A, B - CNNNEWS.NEWS

Hympavzi Recommended for Approval in Europe for Severe Hemophilia A, B

Health and Medical news The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended the granting of marketing authorization for Hympavzi (marstacimab) for treating bleeding episodes in people aged 12 years or older with severe hemophilia A and B. The drug is now pending a final decision from the European Commission. …  » …
Read More